# reload+after+2024-01-22 20:46:06.661012
address1§3545 Cray Court
city§San Diego
state§CA
zip§92121
country§United States
phone§858 332 3410
website§https://www.mirati.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
fullTimeEmployees§587
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Charles M. Baum M.D., Ph.D.', 'age': 65, 'title': 'Founder, President, CEO & Director', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 1069878, 'exercisedValue': 6049346, 'unexercisedValue': 13401795}, {'maxAge': 1, 'name': 'Dr. James G. Christensen Ph.D.', 'age': 55, 'title': 'Executive VP & Chief Scientific Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 1763423, 'exercisedValue': 0, 'unexercisedValue': 4363978}, {'maxAge': 1, 'name': 'Dr. Alan Bart  Sandler M.D.', 'age': 66, 'title': 'Executive VP & Chief Medical Officer', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 591003, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Aaron  Ondrey', 'age': 47, 'title': 'Chief Financial Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Betsy  Gelfand CPA', 'title': 'Chief Accounting Officer, Principal Accounting Officer & VP of Finance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John B. Moriarty Jr., J.D.', 'age': 55, 'title': 'Chief Legal Officer & Corporate Secretary', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Peter  Lee', 'title': 'Chief Compliance Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael E. Paolucci', 'age': 63, 'title': 'Chief People Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Benjamin J. Hickey M.B.A.', 'age': 48, 'title': 'Chief Commercial Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 769026, 'exercisedValue': 147130, 'unexercisedValue': 427055}, {'maxAge': 1, 'name': 'Dr. Kelly  Covello Ph.D.', 'title': 'VP & Head of Medical Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§4
compensationRisk§7
shareHolderRightsRisk§3
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.77
priceToSalesTrailing12Months§108.552505
currency§USD
dateShortInterest§1702598400
forwardEps§-9.12
pegRatio§0.07
exchange§NMS
quoteType§EQUITY
shortName§Mirati Therapeutics, Inc.
longName§Mirati Therapeutics, Inc.
firstTradeDateEpochUtc§1373895000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§e9c1e7b8-e997-3ba1-9039-56fe605a96ca
gmtOffSetMilliseconds§-18000000
targetHighPrice§82.0
targetLowPrice§45.0
targetMeanPrice§61.2
targetMedianPrice§59.0
recommendationMean§2.8
recommendationKey§hold
numberOfAnalystOpinions§15
quickRatio§7.254
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
